Stockreport

TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1 First-in-Human Trial of Umbralisib in The Lancet Oncology

TG Therapeutics, Inc.  (TGTX) 
Last tg therapeutics, inc. earnings: 11/12 07:34 am Check Earnings Report
US:NASDAQ Investor Relations: ir.tgtherapeutics.com
PDF Umbralisib is structurally distinct from other PI3K delta inhibitors with greater selectivity to PI3K delta and unique complementary inhibition of casein kinase-1 (CK1) [Read more]